Available in Spain, Chile, Brazil, United States
This is a Phase IIb, multicentre, randomised, double-blind, dose-finding, parallel group,
double-dummy study aiming to determine the effect on albuminuria, as well as safety and
tolerability, of balcinrenone/dapagliflozin compared with dapagliflozin, when given once
daily on top of other Standard of Care (SoC) to patients with CKD and albuminuria.
Study population will include participants with CKD (eGFR ≥ 25 to < 60 mL/min/1.73 m2)
and UACR > 100 mg/g to ≤ 5000 mg/g. Participants with or without a diagnosis of T2DM and
with or without an SGLT2 inhibitor treatment at screening are eligible for the study.
The study will be conducted at approximately 110 sites in approximately 16 countries
globally.
At least 300 participants will be randomised in order to have 300 evaluable participants.
Participants will be randomised to one of 3 treatment arms in a 1:1:1 ratio:
- Balcinrenone/dapagliflozin 15 mg/10 mg
- Balcinrenone/dapagliflozin 40 mg/10 mg
- Dapagliflozin 10 mg
For each participant, the total duration of participation will be approximately 23 weeks:
an up to 3-week screening period followed by a 12-week treatment period, and an 8-week
follow-up period after end of investigational medicinal product (IMP) treatment.
300Patients around the world